<<<NBIX has presented their data in a far more acceptable manner than RPRX.>>>
That was apparent to me as well. Here NBIX was taking years of time to run multiple, detailed, phase II trials. 2a, 2b, with multiple arms and RPRX was rushing into phase III with a very small, and very quick phase II. I was like, what the heck? How can they justify this for a non-life threatening indication, for a pill that is intended to treat millions of people and still expect FDA approval? As the board as indicated: SCAM.
I am not saying PDLI was a scam, but you can sometimes find unusual things with drugs. I remember PDLI's highly touted drug for cannot even remember the name (like crohns but lower in the stomache, eventual treatment is removal of the colon). Long day.
Anyways, the drug seemed like a miracle drug with early stage results. But the funny thing is, there was no talk in the industry about this drug. No excitement, no mention in the journals, in the industry, in the field. I turned suspicious on the drug despite phase II results that were quite stellar actually. Reasonable results mind you, but very good efficacy and side effect profile.
Turns out the drug was abrupty pulled shortly thereafter. You just have to look for clues sometimes.
On othe rocasions, like with elagolis, it just might be a drug being overlooked due to the disappointing history of indiplon with NBIX as an example. Time will tell. I am definitely going to take a closer look at it.
Tinker
AI
